TAY 018
Alternative Names: TAY-018Latest Information Update: 25 Apr 2022
At a glance
- Originator TOT Biopharm
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 31 Dec 2021 Preclinical trials in Acute myeloid leukaemia in China (Parenteral) before December 2021
- 31 Dec 2021 Preclinical trials in Myelodysplastic syndromes in China (Parenteral) before December 2021
- 31 Dec 2021 Preclinical trials in Non-Hodgkin's lymphoma in China (Parenteral) before December 2021